What Nuclide Therapeutics does

Nuclide Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapies for treatment-resistant cancers. Founded in 2025 as a spin-out from King's College London's Witney Lab, the company is headquartered at St Thomas' Hospital in London and operates with 1–10 employees. It addresses solid tumors that have failed existing precision medicine approaches — initially lung and ovarian cancers — where 18 million new cancer cases annually and 8 million deaths from therapy-resistant disease define a substantial unmet need. The end customers are oncology patients in hospital and clinical trial settings, served through eventual drug commercialization and (potentially) licensing arrangements.

The company's core platform is a proprietary ALDH1A1-targeted radiotheranostics system that pairs diagnostic radionuclides for PET/SPECT imaging with therapeutic radionuclides (alpha and beta emitters) within a single small-molecule targeted compound. This "see and treat" mechanism enables both patient stratification and treatment monitoring, delivering cytotoxic radiation directly to resistant cancer cells while sparing healthy tissue. The product portfolio comprises NTx-010 (diagnostic), NTx-011 (therapeutic, with [131I]NTx-11 as lead candidate), and NTx-043 (next-generation discovery-stage). The platform is protected by at least nine patents: seven cancer-theranostics patents held by CSO Tim Witney, and two cancer-drug-discovery patents held by CEO Muhammet Tanç, with additional licensed radiochemistry IP from CTO Richard Edwards's prior work.

Nuclide is pre-revenue and operates a clinical-stage biotech business model. Capital inflows to date consist of a £5M milestone-based seed round led by Marathon Beteiligungs AG (September 2025) — the largest pre-money valuation of any King's College London spin-out — supplemented by non-dilutive Wellcome and other research grants. Long-term monetization will come from commercialization of proprietary radiopharmaceuticals administered in hospital/oncology settings, with licensing and royalty income as a secondary stream (the team has prior licensing precedent via two commercially licensed imaging agents). Development is supported by strategic partnerships with Enamine (IDD platform and synthetic chemistry), ABX-CRO (clinical operations), UCM Utrecht (academic collaboration), and King's Innovation Catalyst, under a four-co-founder leadership team complemented by CFO Matthias Untisz and advisory board members Andreas Kluge (MD PhD, CEO of Marathon) and Leigh Brody (PhD).

Name

Nuclide Therapeutics

Legal name

Nuclide Therapeutics Ltd

Website

https://nuclidetx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Nuclide Therapeutics is a clinical-stage King's College London spin-out developing ALDH1A1-targeted radiotheranostics — combined diagnostic and therapeutic radiopharmaceuticals — for therapy-resistant solid tumors, with lead candidates NTx-010 and NTx-011 advancing toward first-in-human trials in lung and ovarian cancers.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiation Oncology (HLAKAFAC)

Keywords

• Radiopharmaceutical therapy
• Targeted cancer therapy
• Radiotheranostics platform
• Nuclear medicine oncology
• Therapy-resistant cancer drugs

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Radiopharmaceutical Drug Sales: As a clinical-stage biopharmaceutical company, Nuclide Therapeutics plans to generate revenue through the commercialization of proprietary radiotheranostic drugs. The company is developing ALDH1A1-targeted diagnostic and therapeutic products for therapy-resistant cancers, with lead candidates progressing toward first-in-human trials for lung and ovarian cancers.
2. Licensing and Royalties: The company holds multiple patents in cancer theranostics and has previously licensed imaging agents commercially, indicating potential licensing revenue streams from the company's patented technologies and drug candidates.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Nuclide Therapeutics develops a proprietary radiotheranostics platform that combines diagnostic radionuclides (for PET/SPECT imaging) with therapeutic radionuclides (alpha and beta emitters) conjugated to small molecules that selectively bind to the ALDH1A1 biomarker on therapy-resistant cancer cells. The platform delivers both tumor detection and targeted radiotherapy in a single compound, with lead candidates NTx-010 (diagnostic) and NTx-011 (therapeutic) progressing toward first-in-human trials for lung and ovarian cancers.

Product overview

Nuclide Therapeutics is developing a unified radiopharmaceutical platform based on ALDH1A1-targeted radiotheranostics. The platform combines diagnostic and therapeutic radionuclides with small molecules that bind to a defined biomarker found in resistant tumors, enabling both visualization and elimination of disease. The product portfolio includes NTx-010 (diagnostic), NTx-011 (therapeutic lead candidate [131I]NTx-11), and NTx-043 (next generation discovery), all targeting therapy-resistant solid tumors with applications in lung and ovarian cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• ALDH1A1-Targeted Radiotheranostics Platform

Quantifiable outcome

• Strong preclinical data in lung and ovarian cancers supporting progression to first-in-human trials
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, strategic and major.

• King's College LondoncoreStrategic or Co-development PartnerNuclide Therapeutics is a spin-out from King's College London, exploiting the unique expertise in nuclear medicine described as a 'perfect ecosystem'. The company builds on King's depth of scientific and translational expertise in radiopharmaceuticals. King's Innovation Catalyst provided support for the spin-out formation.
• EnaminecoreTechnology or IntegrationCollaboration began in 2025 to develop targeted radiopharmaceuticals for therapy-resistant cancers. Enamine's synthetic chemistry expertise and large chemical space advantage have helped accelerate Nuclide's drug development milestones, supporting progression from preclinical to clinical trials. Enamine's IDD (Integrated Drug Discovery) Platform is being used to advance the precision radiotheranostics pipeline.
• ABX-CROstrategicStrategic or Co-development PartnerStrategic partner listed on the company's About page, providing development support for the radiopharmaceutical pipeline.
• UCM UtrechtstrategicStrategic or Co-development PartnerStrategic partner listed on the company's About page, representing academic collaboration for the radiopharmaceutical development program.
• Witney LabcoreStrategic or Co-development PartnerOrigin laboratory of CSO Professor Tim Witney at King's College London, from which the company spun out. The lab's research foundation underpins the company's technology platform.
• King's Innovation CatalystmajorStrategic or Co-development PartnerInterim Director Nicolas Huber provided endorsement for the company's £5M funding round, citing King's depth of scientific and translational expertise in radiopharmaceuticals and theranostics.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology indications. Telix is the most directly comparable peer because it operates in the same theranostic model (paired imaging + therapy) and targets solid tumours with unmet need.
• ITM Isotope Technologies Munich: Radiopharmaceutical company combining proprietary medical radioisotope production with targeted radiopharmaceutical pipeline development. ITM is a direct peer because it operates across both the radioisotope supply chain and clinical-stage radiotherapeutics.

Broad incumbents

• Lantheus Holdings: Established radiopharmaceutical company with approved diagnostic products and a growing radiotherapeutic pipeline. Lantheus is a broader incumbent in the radiopharma space with substantially greater scale, manufacturing capacity, and commercial reach than Nuclide.
• Novartis (Radioligand Therapy franchise): Novartis commercialises Lutathera and Pluvicto, the leading approved radioligand therapies, and is expanding its radiopharmaceutical manufacturing footprint. Novartis represents the dominant large-pharma incumbent in the radiotheranostic space.
• Bayer (Xofigo franchise): Bayer markets Xofigo (radium-223), an approved radiopharmaceutical for cancer therapy, and has historically been active in nuclear medicine. As a large pharma, Bayer represents a broad incumbent peer with overlapping modality capabilities.

Emerging players

• Fusion Pharmaceuticals: Clinical-stage radiopharmaceutical company developing targeted alpha therapies, acquired by AstraZeneca. Fusion was a comparable emerging player using targeted radionuclide approaches in oncology before its acquisition.
• Point Biopharma: Clinical-stage radiopharmaceutical company developing PSMA-targeted radioligand therapies, acquired by Eli Lilly. Point was a comparable emerging player with a similar development-stage profile in targeted radioligand therapy.
• Convergent Therapeutics: Clinical-stage radiopharmaceutical company developing next-generation radioligand therapies for solid tumours. Convergent is an emerging peer with a similar development profile and focus on targeted radionuclide approaches.
• Aktis Oncology: Clinical-stage radiopharmaceutical company developing targeted alpha-emitting radiopharmaceuticals for solid tumours. Aktis is a comparable emerging player using targeted radionuclide approaches to address therapy-resistant cancers.
• Ratio Therapeutics: Early-stage radiopharmaceutical company developing targeted radiotherapies for cancer. Ratio is a comparable emerging peer with similar preclinical-to-clinical-stage development of targeted radioligand therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nuclide-therapeutics
• Xx.com/NuclideTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuclide Therapeutics